We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Nextgen | NGG | London | Ordinary Share |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 78.00 | 01:00:00 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 78.00 |
| Top Posts |
|---|
Posted at 11/2/2012 02:50 by stephanie_m Late reported,presume roll over, trade of 218 Million shares. The privelege cost the investor a fee of £3052.s |
Posted at 03/7/2011 18:21 by stephanie_m July 2011's Penny Shares to Watch...This month's penny shares to watch: Why biotech will command the headlines this year... Sareum Holdings (SAR), Valirx (VAL), Nextgen (NGG) Three small cap 'internet cops' waging war on cybercrime... Coreroc (CORO), Datatec (DTC), Digital Barriers (DGB), NCC Group (NCC) To read more about this month's penny share tips take a no obligation trial now and INSTANTLY DOWNLOAD the latest issue PLUS get 3 free special reports! Looking to invest in penny shares? Keep reading to discover my ideas for the coming month... Why biotech will command the headlines this year (This article first appeared in Penny Sleuth in June 2011. Penny Sleuth is an unregulated free e-letter written by Tom Bulford and published by MoneyWeek Limited) This year has seen the dramatic revival of a small sector that has long been written off by most investors. Until now, biotech has been the stuff of nightmares. The medical terminology is baffling. The process of medical discovery is long and expensive. But above all the vast sums of money poured into biotech have paid glorious salaries for chemists and biologists but precious little to outside investors. But a sea change in the industry could change all that. For years big pharma has lead the way in bringing blockbuster drugs to market. But they can't do it any longer. Racked by costs and under threat from generic drug developers, the big pharmaceuticals are stepping back from research. And that opens the door for biotechs. Over the next few years I think it is likely to be biotech stocks that command the headlines in this industry. And the advances underway in biotech could prove hugely lucrative for penny investors... |
Posted at 21/6/2011 07:47 by lady gaga .5p anyone lolHome Log In Register Our Services My Account Contact Help Stockwatch Level 2 Portfolio Charts Shares Magazine Research Share Price Indices Market Scan Company Zone Traders' Room NewsWatch Trades Terminal Alerts Stock Screener Heatmaps News iPhone Forex Director Deals Investors' Room Credit Cards A-Z of Brokers Directory Bookshop Awards 2011 Mortgages ISAs PLUS Simply Chart Broker Notes Forward Diary You are NOT currently logged in . Keyword Company EPIC/TIDM SEDOL/ISIN Tuesday 21 June, 2011 NextGen Group PLC New Assay Launch RNS Number : 7769I NextGen Group PLC 21 June 2011 NextGen Group Plc NextGen Sciences launches multiple protein cerebrospinal fluid (CSF) CNS disease biomarker assay London, UK and Ann Arbor, Michigan, US, 21 June 2011 - NextGen Group plc (AIM:NGG) is pleased to announce that its US-subsidiary NextGen Sciences Inc, a leader in biomarker discovery, measurement and qualification, has launched its first cerebrospinal fluid (CSF) multiple protein (multiplex) assay, csfdiscovery43, for central nervous system (CNS) biomarker discovery and qualification. The assay simultaneously measures 43 human CSF proteins that are thought to have potential as biomarkers in CNS diseases, particularly Alzheimer's, Parkinson's, multiple sclerosis and ALS diseases. The launch of csfdiscovery43 is the next step in NextGen Sciences strategy of becoming a leading player in the growing CNS and oncology biomarker markets. NextGen's assay is based upon its multiple reaction monitoring (MRM) mass spectrometry platform, and generates high quality reproducible data that companies can use in their drug and diagnostic development programmes. In addition to the CNS disease focus, the assay can be used for early-stage biomarker discovery and qualification in other disease areas e.g. traumatic brain injury (TBI). NextGen expects to continue to add proteins to the csfdiscovery43 assay, in addition to developing other disease-focused assay panels, both as proprietary products and with other companies through partnerships and collaborations. Klaus Rosenau, Chairman and CEO of NextGen Group, commented, 'The release of csfdiscovery43 is the next defining step in the development of NextGen Sciences' biomarker business, following its reorganization and release of the plasmadiscovery41 assay in Q1. It demonstrates that we have once again delivered on our plans to develop multiplex protein assays that will help to establish the company as a market leader in biomarker discovery and qualification using its MRM technology. Importantly, this enables us to further target increasing market share from the $600m mass spectrometry based biomarker discovery market. We believe that pharmaceutical, biotechnology and diagnostics companies need high-quality assays relevant to their disease areas to inform their decision-making processes, and NextGen Sciences is currently working on the launch of more such products.' - ENDS - For more information please contact : NextGen Group Klaus Rosenau, Chairman and CEO klaus.rosenau@nextge +49 160 551 6756 Seymour Pierce Jonathan Wright, Nicola Marrin +44 (0) 20 7107 8000 Notes to Editors NextGen Sciences Inc (Ann Arbor, MI, USA) is the subsidiary of NextGen Group PLC, London, UK (AIM: NGG). It provides pharmaceutical, biotechnology and diagnostic companies with rapid and quantitative protein biomarker discovery, measurement and qualification services using mass spectrometry technology. With a rise in the industry focus on personalized medicine and cost-effectiveness, biomarkers are playing an increasing important role in drug discovery, development and patient access, as well as healthcare delivery. The global market for biomarkers is expected to grow to $12.8bn by 2012 (BCC Research), with those for neurological disorders ($3.5bn by 2015, Espicom Healthcare) and oncology ($9.5bn by 2014, www.marketsandmarket This information is provided by RNS The company news service from the London Stock Exchange END MSCSESFMSFFSEFM Investegate takes no responsibility for the accuracy of the information within the site. The announcements are supplied by the denoted source. Queries about the content of an announcement should be directed to the source. Investegate reserves the right to publish a filtered set of announcements. NAV, EMM/EPT, Rule 8 and FRN Variable Rate Fix announcements are filitered from this site. -------------------- © 2011 Financial Express. All rights reserved. Stockwatch Level 2 Portfolio Charts Shares Magazine Research Share Price Indices Market Scan Company Zone Traders' Room NewsWatch Trades Terminal Alerts Stock Screener Heatmaps News iPhone Forex Director Deals Investors' Room Credit Cards A-Z of Brokers Directory Bookshop Awards 2011 Mortgages ISAs PLUS Simply Chart Broker Notes Forward Diary About an ADVFN competitor Ts and Cs Privacy Policy Investment Warning Content Standards Corporate Solutions Advertise With Us Site Map © 2011 an ADVFN competitor Register now for FREE Share Prices, Stock Quotes, Charts, Bulletin Boards, Indices, Watchlists, Portfolio, Market News, Research or see our Premium Services including Level 2, Terminal and much more. Follow us on Twitter |
Posted at 25/5/2011 11:05 by lady gaga Weve got a plug here.It looks like Tom likes us. The discovery that points to biotech's incredible revival... (This article first appeared in Penny Sleuth on 10 February 2011. Penny Sleuth is an unregulated free e-letter written by Tom Bulford and published by MoneyWeek Limited) 2010 was the year of the junior miner. Every week saw some plucky explorer score unbelievable gains. But this year is likely to be different, and I've got my eye on a few other sectors that I think could see fantastic successes in 2011. I've talked about food stocks and the remarkable recovery in UK manufacturing. But one sector that is really beginning to look exciting is biotech. Dormant for years and abandoned by investors as a non-starter, biotech looks to be on the cusp of a thrilling revival. After a string of dramatic announcements in recent months, it seems that investors have discovered a newfound enthusiasm for these stocks. Just look at what happened this week when drug researcher SAREUM HOLDINGS (SAR) revealed news of another exciting breakthrough... The discovery that points to Biotech's extraordinary revival On Monday Dr Tim Mitchell, Chief Executive of the Cambridge based drug researcher, reported that its Aurora+FLT3 Kinase programme had, in a pre-clinical in-vivo study, appeared to slow the progress of cancer. Ten leukaemia patients were treated with this compound and their 'leukaemia regressed to such an extent that no detectable cancer could be found in any of the cases treated'. By contrast for those who did not receive Sareum's compound their leukaemia 'increased five to fifteen fold'. That was enough to send Sareum's share price multiplying. Having drifted along for months at a price of about 0.25p, the shares took off, hitting 1.65p the following day and 4.79p on Wednesday. It has slipped back a little today. But those lucky enough to have been holding the shares and smart enough to have got out at the top could have multiplied their money nineteen-fold in the space of just three days. No less impressive was the extraordinary volume of shares that were traded. On Wednesday 1,142,362,883 Sareum shares were traded, representing over 80% of its entire issued capital, and the excitement spread elsewhere. Oxford-based PHYSIOMICS (PYC) has developed a simulation platform that can show how a tumour will react to drug exposure. It saw its share price surge from 0.25p to an intra-day high of 0.68p The US company NEXTGEN (NGG), which offers a suite of services that can increase the traditionally low success rates associated with biomarker development, flew from 0.11p to a high of 0.53p VALIRX (VAL), which focuses on the epigenomic analysis and treatment of cancer (the epigenome consists of chemical compounds that modify, or mark, the genome in a way that tells it what to do) almost doubled to 0.53p This is an extraordinary revival for a sector that has been languishing for so long that most investors have given it up. But you need to be very careful here... A sector shot through with risk - and scintillating rewards A cure for cancer is the equivalent of finding a river of liquid gold. But still, the biotech industry is fraught with danger. It eats up money, and genuine successes are few and far between. A few years ago high hopes were held for ANTISOMA (ASM), also a company looking for successful cancer drugs. This week it was described as a company 'that develops drugs that do not work'. That's a harsh but fair verdict on a company that has seen its share price sink from 36p to 2.2p over the last twelve months. Those who rushed into Sareum are already being brought face to face with some of the realities of biotech life. Today the company took advantage of the surge of interest to tap shareholders for £500,000, through the sale of 500m new shares at a penny a time. And a more careful reading of Sareum's Monday revelation shows that 'at six weeks following treatment, no detectable cancer could be found in two of the ten examples dosed with the Sareum compound. In the remaining eight treated examples, the average time taken for the leukaemia to increase five-fold was six weeks, compared to two weeks in the untreated cases'. So while Sareum's treatment seems to have some advantages over others, it appears to limit the spread of cancer, rather than kill it off completely. How marvellous it would be if Sareum had a cancer cure! But shareholders should prepare for a long and bumpy ride. Biotech research is a laborious process. While successful developments in this area often improve upon existing therapies, few provide a total cure. In time Sareum will need to find licensing partners, most probably big pharma companies with deep pockets. As big pharma cuts back on its own research spending, it is increasingly looking for small biotechs to do the early work, but the big boys do not move fast. |
Posted at 13/5/2011 09:18 by still waiting VAL looks better value with an investor event next week, news may be released mon/tues before the meeting..dyor. |
Posted at 13/4/2011 23:14 by citytrader 007 If this was my thread i'd do it, this person all over these boards has gotten quite a reputation for falsifying and lying, even today with the 30 odd percent claim.SAR and PYC were both traps too, contrary to belief, you'd think he/she "packeted" from those too, and when I stated what i'd made in various threads I was shot down, but this was ok to "certain" people to do it. You'll notice I do not post there now, simply because im out, although some still do because there stuck in it, caught out on their own ramping, a bit like today you may say ? The chances are, he/she sold here on panic later in the morning, rather than having balls and hanging on - proving a pump and dump theory so much loved by some, and or simply holding silent if that was the case that IT sold, he/she decided to lie about the whole thing, look at all posts since your pre-opening all through the day, says enough right ? The thing being, is now he/she has dropped so many clangers all over ADV, i'd guess in a short amount of time, the name will dissappear and another created, with the same BS none the less !! You may also agree, that he/she seems to have a few followers in EVERY THREAD posted in, you could call them ALTS possibly, or alternate characters of the same person, either way, wherever IT posts, reverse what IT says and your about right, DO NOT listen, as today you have learnt - as with most of ADV forums now, are simply full of BS and lies to secure a win, that is never in your favour, like the peas under the cups trick and guess where it is, simply a con. If your reading this now, i'd steer well clear of shares that IT is in, a pure danger to have in any thread for any honest true investor reading in. TO THE MOD - please remove this if you have to, no probs, but also do the right thing aswell. |
Posted at 06/4/2011 17:59 by lokesh8 Settlement as of 06/04/2011, at 5:45 p.m.Nextgen Group Plc settles around previous levels, slipping 0.00% at close of trade. The share started the day in neutral territory, and continued to move sideways during the session, before finally perking up to finish at 0.34, the day's highest price. On a weekly basis, the stock is trending higher than the UK FTSE All Share. For the moment, therefore, Nextgen Group Plc clearly appeals more to investors than the benchmark. Status and Trend Analysis While the medium-term picture confirms Nextgen Group Plc's negative trend, the short term reveals the possibility of a timid upswing to first resistance in the 0.3533 area. First support is identified at 0.3133. Further positive cues could signal an upward movement with a target of 0.3933. Risk Analysis The Nextgen Group Plc stock's level of risk turns out to be fairly high as prices have recently been deviating widely. The stock would therefore suit investors who, in their pursuit of big gains, are well aware that they also risk large losses. Daily volume is subdued at 1,114,077, below the 1-month moving average for volume of 3,831,723. Resistance 2 0.3933 Resistance 1 0.3533 Closing price 0.34 Support 1 0.3133 Support 2 0.2867 Volatility (daily) 28.64 Value At Risk % 66.62 Performance (weekly) 14.14 % UK FTSE All Share (weekly) 1.19 % Performance (yearly) 100.00 % |
Posted at 05/4/2011 18:40 by lokesh8 Settlement as of 05/04/2011, at 5:45 p.m.A flat performance from Nextgen Group Plc, which edges down 0.00%. The security opened on a par with the previous close and showed considerable stability throughout trading, before closing uptrend near its high of 0.347. Nextgen Group Plc's weekly trend is more sluggish than the benchmark's movements. The downswing could create selling opportunities for Nextgen Group Plc stock. Status and Trend Analysis Although the medium-term outlook for Nextgen Group Plc remains negative, we find an increasing upward movement in the short term, with the most immediate resistance at 0.3533. Support is at 0.3133. The technicals favour a new upswing to the 0.3933 area. Risk Analysis With a daily volatility of 28.72 the Nextgen Group Plc share has primarily caught the attention of risk-loving investors. Trading opportunities should primarily be sought in a short-term perspective, as the intraday volume of 731,308 is below the volume moving average of 3,799,582 for the last month. Resistance 2 0.3933 Resistance 1 0.3533 Closing price 0.34 Support 1 0.3133 Support 2 0.2867 Volatility (daily) 28.72 Value At Risk % 66.81 Performance (weekly) -0.16 % UK FTSE All Share (weekly) 1.76 % Performance (yearly) 100.00 % |
Posted at 18/2/2011 20:53 by sonicx Stephanie_M: It may be an idea to incorporate some of this info into the top of the thread?I'm not here to ramp up the price, but can't see the harm in pointing out factual relevant information in order to help investors make an informed decision. Do you agree? Cheers sonicx |
Posted at 18/2/2011 20:50 by sonicx I've put this info on the other thread it may be of use to any potential investors out there?Just a bit of info for any current holders or prospective buyers of this company: Over the past 8 trading days the share price has risen from 0.12p to 0.42p. Thats a rise of 250% or an average of 30% a day, despite pleas from the company that "they know nothing". The charts and prospects of the rise continuing next week look good, so if you want to get in below 1p, I suggest you bite the bullet and do it, otherwise we may be above 1p before you can blink. If we get some extra positive news in the meantime then anything is possible? p.s. someone on the iii bb mentioned that 85% of the shares are in safe hands and won't be traded. How true that is I don't really know, anyone here know? Cheers and have a nice weekend! sonicx Growth Company Investor spoke to Klaus Rosenau, the German CEO and veteran of a number of German IT concerns. Enthusing that he has 'a lot of contacts' within the investment industry Rosenau remarked on the recent excitement in the AIM biotech sector. 'Biotech is taking off at the moment - this is because those analysing the market as a whole realise that now is probably the best time to jump on the train'... I've found the info and it looks to be true (below) It would seem that as long as the company is progressing nicely, (and there is no reason to doubt this) then there is no reason for the trust fund to sell (family Trust Select) whoever they are? They seem to have held a large chunk of the company for a while anyway. So in reality we (us) pi's have only the 14% left to play about with on a day to day basis. I'm not sure what would happen if an investment fund other than the one listed below wanted a share of the action, now that would be an eye opener I'm sure? I'm seriously considering upping my stake based on this information. The Placing Shares are being subscribed for by Family Trust Select - FIS - Teilfonds Zeus, a Luxembourg fund managed Family Trust Management S.a.r.l. (the "Family Trust Select"). On completion of the Placing, Family Trust Select will hold 82.43 per cent. of the then issued share capital of the Company and if Family Trust Select was to immediately exercise all of the warrants it holds after the Placing, it would hold 89.69 per cent of the then issued share capital of the Company. Also in addition to the above, the CEO would appear to have his head screwed on, and is involved in a number of IT companies, which probably helps the business no end. (you can't put a value on experience and contacts), and I would expect him to have many contacts in this field. A brief summary below: BACKGROUND* Klaus Günter Erich Rosenau serves as Chairman and Chief Executive Officer of OAR Consulting AG and NextGen Sciences Ltd. Mr. Rosenau also serves as Chairman and Chief Executive Officer of Nextgen Group PLC at NextGen Sciences Ltd. He has more than 21 years of experience in development and marketing of innovative technologies. He was engaged in the implementation and development of new technologies in a variety of leadership positions. In 1993, Mr. Rosenau founded OAR Consulting GmbH and led it to a successful IPO in 1998 and created an international operation supplying innovative solutions for information technology. He initiated several mergers and consequently improved the service spectrum of his company. Since 2003, he has supported IT-related companies in the development of their business strategy, financing and project planning. He serves as a Director of OAR Consulting AG . In 2000, his success was honored with the award "finalist entrepreneur of the year. |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
